Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings Results

Enanta Pharmaceuticals (NASDAQ:ENTA) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16), Zacks reports. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%.

Enanta Pharmaceuticals Stock Up 0.3%

Enanta Pharmaceuticals stock traded up $0.04 during trading hours on Monday, hitting $13.81. The stock had a trading volume of 147,586 shares, compared to its average volume of 195,833. The company has a 50-day moving average of $13.08 and a two-hundred day moving average of $13.42. The company has a market cap of $401.59 million, a PE ratio of -5.33 and a beta of 0.98. Enanta Pharmaceuticals has a fifty-two week low of $6.45 and a fifty-two week high of $17.15.

Institutional Trading of Enanta Pharmaceuticals

Several institutional investors have recently modified their holdings of ENTA. Virtu Financial LLC bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter valued at approximately $220,000. Invesco Ltd. lifted its position in Enanta Pharmaceuticals by 325.2% in the fourth quarter. Invesco Ltd. now owns 253,811 shares of the biotechnology company’s stock worth $4,003,000 after purchasing an additional 194,113 shares during the period. Krensavage Asset Management LLC lifted its position in Enanta Pharmaceuticals by 30.8% in the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after purchasing an additional 651,946 shares during the period. Wellington Management Group LLP acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth $997,000. Finally, Opaleye Management Inc. acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth $1,183,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ENTA. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, June 23rd. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.29.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.